CD8A and neoplasm: Considering the prominent role of Brd4 in HIV-1 latency and tumor therapy and the essential role of CD8+ T cells in antiviral/antitumor immunity, it is urgent to clearly evaluate the effect of Brd4 inhibition on CD8+ T cell function and differentiation in vivo.